PMID- 35767376 OWN - NLM STAT- MEDLINE DCOM- 20220831 LR - 20220901 IS - 1097-0045 (Electronic) IS - 0270-4137 (Linking) VI - 82 IP - 14 DP - 2022 Oct TI - Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer. PG - 1322-1330 LID - 10.1002/pros.24406 [doi] AB - BACKGROUND: Docetaxel-related adverse events (AEs) such as neutropenia and febrile neutropenia (FN) can be life-threatening. A previous in vivo study raised the hypothesis that the castration status affects the rate of hematologic AEs. We aimed to investigate the impact of castration status on the incidence of docetaxel-related AE in metastatic prostate cancer (mPCa) patients. METHODS: We retrospectively analyzed the records of 265 mPCa patients treated with docetaxel, comprising 92 patients with metastatic hormone-sensitive prostate cancer (mHSPC) and 173 patients with metastatic castration-resistant prostate cancer (mCRPC) between January 2015 and December 2021. Common terminology Criteria for Adverse Events (CTCAE) was applied to evaluate AEs. We analyzed the differential incidences between mHSPC and mCRPC, and risk factors of hematologic and nonhematologic AEs using a logistic regression model. RESULTS: The rate of patients who received primary prophylaxis against neutropenia was higher in those with the mHSPC compared with those with the mCRPC (7.5% vs. 33%, p < 0.001). Among the patients without primary prophylaxis, incidence rates of severe neutropenia (CTCAE >/= Grade3) and FN were 89% and 16% in patients with mCRPC compared to 81% and 18% in those with mHSPC. Logistic regression analysis revealed that age >/= 75 years and failure to provide primary prophylaxis were independent risk factors of severe neutropenia (odds ratio [OR]: 2.39, 95% confidential interval [CI]: 1.10-5.18 and OR: 15.8, 95% CI: 7.23-34.6, respectively). Eastern Cooperative Oncology Group Performance Status (ECOG-PS) >== 1 was an independent risk factor of FN (OR: 2.26, 95% CI: 1.13-4.54). Castration status (mHSPC vs. mCRPC) was not associated with the risks of severe neutropenia and FN. CONCLUSIONS: Castration status did not affect the risk of severe neutropenia or FN in mPCa patients treated with docetaxel regardless of the disease state. Failure to provide primary prophylaxis and advanced patient age are independent risk factors of severe neutropenia; while patients with poor PS are more likely to develop FN. These findings may help guide the clinical decision-making for proper candidate selection of docetaxel treatment. CI - (c) 2022 Wiley Periodicals LLC. FAU - Yanagisawa, Takafumi AU - Yanagisawa T AUID- ORCID: 0000-0002-7410-0712 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. FAU - Kimura, Takahiro AU - Kimura T AUID- ORCID: 0000-0002-5673-1553 AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Hata, Kenichi AU - Hata K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. AD - Department of Urology, Atsugi City Hospital, Kanagawa, Japan. FAU - Narita, Shintaro AU - Narita S AD - Department of Urology, Akita University School of Medicine, Akita, Japan. FAU - Hatakeyama, Shingo AU - Hatakeyama S AD - Division of Advanced Blood Purification Therapy, Department of Urology, Hirosaki University Graduate School of Medicine, Aomori, Japan. FAU - Enei, Yuki AU - Enei Y AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Atsuta, Mahito AU - Atsuta M AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Mori, Keiichiro AU - Mori K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Obayashi, Koki AU - Obayashi K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Yoshihara, Kentaro AU - Yoshihara K AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kondo, Yosuke AU - Kondo Y AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Oguchi, Takahiro AU - Oguchi T AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Sadakane, Ibuki AU - Sadakane I AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Habuchi, Tomonori AU - Habuchi T AD - Department of Urology, Akita University School of Medicine, Akita, Japan. FAU - Ohyama, Chikara AU - Ohyama C AD - Division of Advanced Blood Purification Therapy, Department of Urology, Hirosaki University Graduate School of Medicine, Aomori, Japan. FAU - Shariat, Shahrokh F AU - Shariat SF AD - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. AD - Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. AD - Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. AD - Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. AD - Department of Urology, Weill Cornell Medical College, New York, New York, USA. AD - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. FAU - Egawa, Shin AU - Egawa S AD - Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20220629 PL - United States TA - Prostate JT - The Prostate JID - 8101368 RN - 0 (Antineoplastic Agents) RN - 15H5577CQD (Docetaxel) SB - IM MH - Aged MH - *Antineoplastic Agents/adverse effects MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Docetaxel/adverse effects MH - Humans MH - Male MH - *Neutropenia/chemically induced/drug therapy/epidemiology MH - Orchiectomy MH - *Prostatic Neoplasms, Castration-Resistant/drug therapy/pathology MH - Retrospective Studies MH - Risk Factors MH - Treatment Outcome OTO - NOTNLM OT - adverse events OT - docetaxel OT - metastatic castration-resistant prostate cancer OT - metastatic hormone-sensitive prostate cancer OT - neutropenia EDAT- 2022/06/30 06:00 MHDA- 2022/09/01 06:00 CRDT- 2022/06/29 12:13 PHST- 2022/05/31 00:00 [revised] PHST- 2022/03/26 00:00 [received] PHST- 2022/06/14 00:00 [accepted] PHST- 2022/06/30 06:00 [pubmed] PHST- 2022/09/01 06:00 [medline] PHST- 2022/06/29 12:13 [entrez] AID - 10.1002/pros.24406 [doi] PST - ppublish SO - Prostate. 2022 Oct;82(14):1322-1330. doi: 10.1002/pros.24406. Epub 2022 Jun 29.